The new kid on the block: RET in lung cancer.
نویسندگان
چکیده
RET has recently been identified as a potential new oncogenic driver in a subset of patients with non-small cell lung cancer (NSCLC). In this issue of Cancer Discovery, Drilon and colleagues report preliminary trial data with a RET inhibitor in RET fusion-positive NSCLC, validating RET as a therapeutic target in lung cancer.
منابع مشابه
RET proto-oncogene mutations in the diagnosis of medullary thyroid cancer: a review article
Medullary thyroid cancer accounts for 5-10% of thyroid carcinomas. RET proto-oncogene mutations occur in all of the hereditary MTCs and about 66% of the sporadic MTCs. So, the detection of the RET mutations is necessary for rapid and proper diagnosis and treatment. This systematic review seeks to find a comprehensive list of RET gene mutations in the diagnosis of medullary thyroid cancer. The ...
متن کاملDetection of lung cancer using CT images based on novel PSO clustering
Lung cancer is one of the most dangerous diseases that cause a large number of deaths. Early detection and analysis can be very helpful for successful treatment. Image segmentation plays a key role in the early detection and diagnosis of lung cancer. K-means algorithm and classic PSO clustering are the most common methods for segmentation that have poor outputs. In t...
متن کاملتخمین نرخ بروز استاندارد شده سنی سرطان ریه در ایران برای سال‌های 2014 و 2030
Introduction: lung cancer is the most deadly and the most expensive cancer all around the world. Limited studies have been conducted in the survey of incidence rate for lung cancer in IRAN. National report of cancer registry in IRAN (report 2008) indicates that mean value of ASR of lung cancer is 5.23 for men and women (7.09 for men and 3.38 for women). These values are so different from the va...
متن کاملResponse to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.
The discovery of RET fusions in lung cancers has uncovered a new therapeutic target for patients whose tumors harbor these changes. In an unselected population of non-small cell lung carcinomas (NSCLCs), RET fusions are present in 1% to 2% of cases. This incidence increases substantially, however, in never-smokers with lung adenocarcinomas that lack other known driver oncogenes. Although precli...
متن کاملEGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells
PURPOSE Rearrangement of the proto-oncogene rearranged during transfection (RET) has been newly identified potential driver mutation in lung adenocarcinoma. Clinically available tyrosine kinase inhibitors (TKIs) target RET kinase activity, which suggests that patients with RET fusion genes may be treatable with a kinase inhibitor. Nevertheless, the mechanisms of resistance to these agents remai...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Cancer discovery
دوره 3 6 شماره
صفحات -
تاریخ انتشار 2013